Product Name
FGFR3, siRNA
Full Product Name
FGFR3 siRNA (Human)
Product Synonym Names
JTK4; Fibroblast growth factor receptor 3; FGFR-3; CD antigen CD333
Product Gene Name
FGFR3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P22607
Specificity
FGFR3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human FGFR3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of FGFR3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
FGFR3 sirna
siRNA to inhibit FGFR3 expression using RNA interference
Applications Tested/Suitable for FGFR3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for FGFR3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_000133.1
[Other Products]
NCBI GenBank Nucleotide #
NM_000142.4
[Other Products]
UniProt Primary Accession #
P22607
[Other Products]
UniProt Secondary Accession #
Q14308; Q16294; Q16608; Q59FL9; D3DVP9; D3DVQ0[Other Products]
UniProt Related Accession #
P22607[Other Products]
Molecular Weight
85,083 Da
NCBI Official Full Name
fibroblast growth factor receptor 3 isoform 1
NCBI Official Synonym Full Names
fibroblast growth factor receptor 3
NCBI Official Symbol
FGFR3??[Similar Products]
NCBI Official Synonym Symbols
ACH; CEK2; JTK4; CD333; HSFGFR3EX
??[Similar Products]
NCBI Protein Information
fibroblast growth factor receptor 3
UniProt Protein Name
Fibroblast growth factor receptor 3
UniProt Synonym Protein Names
CD_antigen: CD333
Protein Family
Fibroblast growth factor receptor
UniProt Gene Name
FGFR3??[Similar Products]
UniProt Synonym Gene Names
JTK4; FGFR-3??[Similar Products]
UniProt Entry Name
FGFR3_HUMAN
NCBI Summary for FGFR3
This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia. Three alternatively spliced transcript variants that encode different protein isoforms have been described. [provided by RefSeq, Jul 2009]
UniProt Comments for FGFR3
FGFR3: a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3. Activated FGFR3 found in 30% of bladder cancers and several cervical cancers, but not in other tumors. Two mutations found in colorectal cancer.
Protein type: Protein kinase, tyrosine (receptor); Membrane protein, integral; EC 2.7.10.1; Protein kinase, TK; Kinase, protein; TK group; FGFR family
Chromosomal Location of Human Ortholog: 4p16.3
Cellular Component: Golgi apparatus; internal side of plasma membrane; transport vesicle; cell surface; focal adhesion; lysosome; integral to plasma membrane; perinuclear region of cytoplasm; endoplasmic reticulum; plasma membrane; extracellular region; nucleus
Molecular Function: protein binding; fibroblast growth factor binding; fibroblast growth factor receptor activity; protein-tyrosine kinase activity; ATP binding
Biological Process: peptidyl-tyrosine phosphorylation; nerve growth factor receptor signaling pathway; somatic stem cell maintenance; protein amino acid autophosphorylation; negative regulation of transcription from RNA polymerase II promoter; bone mineralization; positive regulation of tyrosine phosphorylation of Stat3 protein; substantia nigra development; positive regulation of MAPKKK cascade; inner ear receptor cell differentiation; cell-cell signaling; positive regulation of neuron apoptosis; forebrain development; positive regulation of cell proliferation; chondrocyte differentiation; morphogenesis of an epithelium; response to axon injury; skeletal development; negative regulation of epithelial cell proliferation; endochondral ossification; negative regulation of developmental growth; epidermal growth factor receptor signaling pathway; phosphoinositide-mediated signaling; fibroblast growth factor receptor signaling pathway; myelination in the central nervous system; MAPKKK cascade; positive regulation of phosphoinositide 3-kinase activity; digestive tract morphogenesis; JAK-STAT cascade; positive regulation of tyrosine phosphorylation of Stat1 protein; positive regulation of protein ubiquitination; negative regulation of smoothened signaling pathway; negative regulation of mitosis; negative regulation of astrocyte differentiation; insulin receptor signaling pathway; innate immune response; lens morphogenesis in camera-type eye; positive regulation of endothelial cell proliferation; positive regulation of cell differentiation
Disease: Bladder Cancer; Achondroplasia; Hypochondroplasia; Muenke Syndrome; Achondroplasia, Severe, With Developmental Delay And Acanthosis Nigricans; Cervical Cancer; Thanatophoric Dysplasia, Type I; Colorectal Cancer; Crouzon Syndrome With Acanthosis Nigricans; Camptodactyly, Tall Stature, And Hearing Loss Syndrome; Lacrimoauriculodentodigital Syndrome; Thanatophoric Dysplasia, Type Ii; Testicular Germ Cell Tumor; Nevus, Epidermal
Research Articles on FGFR3
1. BGN is a factor secreted by peritubular cells to modulate FGFR3c signaling and thus contributes to the regulation of spermatogonial maintenance
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
